HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
50 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
HDAC1
histone deacetylase 1
Chromosome 1 · 1p35.2-p35.1
NCBI Gene: 3065Ensembl: ENSG00000116478.14HGNC: HGNC:4852UniProt: Q13547
1,335PubMed Papers
20Diseases
14Drugs
1Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneTranscription Factor
RESEARCH IMPACT
Highly StudiedTrending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
negative regulation of canonical Wnt signaling pathwaypositive regulation of intracellular estrogen receptor signaling pathwaycore promoter sequence-specific DNA bindingtranscription corepressor bindingneoplasmmultiple myelomaCutaneous T-cell lymphomaDuchenne muscular dystrophy
✦AI Summary

HDAC1 is a histone deacetylase that catalyzes lysine deacetylation on core histones (H2A, H2B, H3, H4), establishing epigenetic repression marks critical for transcriptional regulation, cell cycle progression, and development 1. HDAC1 functions within multiprotein complexes, including the NuRD chr1 remodeling complex 2 and SIN3B complex, where it regulates histone acetylation at transcribed regions 3. Beyond histones, HDAC1 deacetylates non-histone proteins including RELA, SP1, SP3, and STAT3, modulating their transcriptional activities 4. HDAC1 also exhibits protein-lysine deacylase activity, performing decrotonylation and delactylation of histones 5. Clinically, HDAC1 dysfunction associates with multiple diseases. In colorectal cancer, HDAC1 lactylation regulates ferroptosis resistance through FSP1 mRNA degradation pathways 6. HDAC1 controls dendritic cell development and anti-tumor immunity by regulating transcription factors IRF4, IRF8, and SPIB; HDAC1 deletion enhances cDC2 maturation and CD8+ T cell-mediated immunity 7. In diabetic kidney disease, HDAC1 inhibition restores autophagy and alleviates endothelial-mesenchymal transition via PI3K/AKT/mTOR pathway suppression 8. HDAC1 also modulates drug resistance in lung adenocarcinoma and regulates host-pathogen interactions during Leishmania infection 910. Additionally, HDAC1 mediates anti-inflammatory responses to anesthetic isoflurane in monocytes through NF-κB regulation 11.

Sources cited
1
HDAC1 is a histone deacetylase that catalyzes lysine deacetylation on core histones (H2A, H2B, H3, H4), establishing epigenetic repression marks critical for transcriptional regulation, cell cycle progression, and development .
PMID: 16762839
2
HDAC1 functions within multiprotein complexes, including the NuRD chr1 remodeling complex and SIN3B complex, where it regulates histone acetylation at transcribed regions .
PMID: 16428440
3
HDAC1 functions within multiprotein complexes, including the NuRD chr1 remodeling complex and SIN3B complex, where it regulates histone acetylation at transcribed regions .
PMID: 21041482
4
Beyond histones, HDAC1 deacetylates non-histone proteins including RELA, SP1, SP3, and STAT3, modulating their transcriptional activities .
PMID: 12837748
5
HDAC1 also exhibits protein-lysine deacylase activity, performing decrotonylation and delactylation of histones .
PMID: 28497810
6
In colorectal cancer, HDAC1 lactylation regulates ferroptosis resistance through FSP1 mRNA degradation pathways .
PMID: 39888307
7
HDAC1 controls dendritic cell development and anti-tumor immunity by regulating transcription factors IRF4, IRF8, and SPIB; HDAC1 deletion enhances cDC2 maturation and CD8+ T cell-mediated immunity .
PMID: 38829740
8
In diabetic kidney disease, HDAC1 inhibition restores autophagy and alleviates endothelial-mesenchymal transition via PI3K/AKT/mTOR pathway suppression .
PMID: 36774842
9
Additionally, HDAC1 mediates anti-inflammatory responses to anesthetic isoflurane in monocytes through NF-κB regulation .
PMID: 31950542
Disease Associationsⓘ20
neoplasmOpen Targets
0.58Moderate
multiple myelomaOpen Targets
0.57Moderate
Cutaneous T-cell lymphomaOpen Targets
0.56Moderate
Duchenne muscular dystrophyOpen Targets
0.52Moderate
unspecified peripheral T-cell lymphomaOpen Targets
0.52Moderate
T-cell non-Hodgkin lymphomaOpen Targets
0.51Moderate
cancerOpen Targets
0.50Moderate
mature T-cell and NK-cell non-Hodgkin lymphomaOpen Targets
0.46Moderate
Rett syndromeOpen Targets
0.38Weak
acute myeloid leukemiaOpen Targets
0.37Weak
lymphomaOpen Targets
0.37Weak
renal cell carcinomaOpen Targets
0.37Weak
breast cancerOpen Targets
0.36Weak
myelodysplastic syndromeOpen Targets
0.30Weak
Hodgkins lymphomaOpen Targets
0.30Weak
lung cancerOpen Targets
0.30Weak
polycythemia veraOpen Targets
0.29Weak
follicular lymphomaOpen Targets
0.29Weak
mesotheliomaOpen Targets
0.28Weak
ovarian carcinomaOpen Targets
0.27Weak
Pathogenic Variants1
NM_004964.3(HDAC1):c.461A>G (p.Asn154Ser)Likely pathogenic
Inborn genetic diseases
★☆☆☆2013→ Residue 154
View on ClinVar ↗
Drug Targets14
ABEXINOSTATPhase III
Histone deacetylase inhibitor
follicular lymphoma
BELINOSTATApproved
Histone deacetylase inhibitor
T-cell non-Hodgkin lymphoma
CUDC-101Phase I
Epidermal growth factor receptor erbB1 inhibitor
ENTINOSTATApproved
Histone deacetylase inhibitor
neoplasm
FIMEPINOSTATPhase II
Histone deacetylase inhibitor
lymphoma
GIVINOSTATApproved
Histone deacetylase inhibitor
Duchenne muscular dystrophy
GIVINOSTAT HYDROCHLORIDEApproved
Histone deacetylase inhibitor
Duchenne muscular dystrophy
MOCETINOSTATPhase II
Histone deacetylase 11 inhibitor
non-small cell lung carcinoma
PANOBINOSTATApproved
Histone deacetylase inhibitor
multiple myeloma
PANOBINOSTAT LACTATEApproved
Histone deacetylase inhibitor
multiple myeloma
QUISINOSTATPhase II
Histone deacetylase inhibitor
ROMIDEPSINApproved
Histone deacetylase inhibitor
T-cell non-Hodgkin lymphoma
TACEDINALINEPhase II
Histone deacetylase inhibitor
VORINOSTATApproved
Histone deacetylase 2 inhibitor
T-cell non-Hodgkin lymphoma
Related Genes
REREProtein interaction100%CTBP1Protein interaction100%DDIT3Protein interaction100%SUV39H1Protein interaction100%TP53Protein interaction100%GATAD2AProtein interaction100%
Tissue Expression6 tissues
Ovary
100%
Bone Marrow
96%
Liver
76%
Lung
76%
Heart
52%
Brain
40%
Gene Interaction Network
Click a node to explore
HDAC1RERECTBP1DDIT3SUV39H1TP53GATAD2A
PROTEIN STRUCTURE
Preparing viewer…
PDB7SME · 2.64 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.53Moderately Constrained
pLIⓘ
0.95Intolerant
Observed/Expected LoF0.33 [0.21–0.53]
RankingsWhere HDAC1 stands among ~20K protein-coding genes
  • #103of 20,598
    Most Researched1,335 · top 1%
  • #183of 1,025
    FDA-Approved Drug Targets8 · top quartile
  • #4,600of 5,498
    Most Pathogenic Variants1
  • #3,302of 17,882
    Most Constrained (LOEUF)0.53 · top quartile
Genes detectedHDAC1
Sources retrieved50 papers
Response time—
📄 Sources
50▼
1
Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer.
PMID: 39888307
Adv Sci (Weinh) · 2025
1.00
2
The deacetylases HDAC1/HDAC2 control JAK2
PMID: 40877230
Signal Transduct Target Ther · 2025
0.90
3
The histone deacetylase HDAC1 controls dendritic cell development and anti-tumor immunity.
PMID: 38829740
Cell Rep · 2024
0.90
4
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
PMID: 16960727
Histochem Cell Biol · 2007
0.84
5
HDAC1 and HDAC2 Are Involved in Influenza A Virus-Induced Nuclear Translocation of Ectopically Expressed STAT3-GFP.
PMID: 39861822
Viruses · 2024
0.82